Jan 09, 2026
Casey’s Food Strategy Wins Out While Murphy USA Struggles With Fuel Trends

Investors are closely watching the convenience retail sector as new research highlights shifting demand and competitive pressures. BofA Securities analyst Lisa K. Lewandowski initiated coverage on Murphy USA Inc. (NYSE:MUSA) and Casey’s General Stores, Inc. (NASDAQ:CASY). Casey’s General Stores Analyst…

Jan 09, 2026
Cava Is Poised To Outperform In 2026, Says Analyst

Cava Group Inc. (NYSE:CAVA) is drawing renewed attention from Wall Street as analysts look beyond near-term headwinds and focus on the restaurant chain's long-term growth potential. Telsey Advisory Group analyst Sarang Vora initiated coverage on Cava Group with an Outperform…

Jan 09, 2026
Chipotle’s High-Protein Push Targets GLP-1 Users, Analysts See Upside

Chipotle Mexican Grill, Inc. (NYSE:CMG) shares are trading higher on Friday. The restaurant chain is accelerating its global expansion as it targets long-term growth through new restaurant openings and digital-first formats. Analysts have turned their focus to the company’s international…

Jan 09, 2026
Tilray Valuation Attractive With Strong Growth Overseas, Analyst Says

Tilray Brands Inc. (NASDAQ:TLRY) on Thursday reported quarterly earnings of one cent per share, which beat the Street estimate for a loss of 20 cents. Quarterly revenue came in at $217.51 million, which beat the consensus estimate of $210.95 million. Cannabis net revenue increased…

Jan 09, 2026
These Analysts Revise Their Forecasts On TD Synnex After Q4 Results

TD SYNNEX Corporation (NYSE:SNX) posted upbeat fourth-quarter results on Thursday. The information technology services provider reported fourth-quarter revenue of $17.4 billion, which surpassed the analysts' expectations of $16.9 billion and also marked a 9.7% increase year over year (Y/Y). TD…

Jan 09, 2026
Bad News For Competitor Turns Into Big Win For ARS Pharma Stock

ARS Pharmaceuticals Inc. (NASDAQ:SPRY) stock rose Friday in reaction to a negative update for its rival Aquestive Therapeutics Inc. (NASDAQ:AQST). The U.S. Food and Drug Administration (FDA) identified deficiencies in Aquestive’s Anaphylm’s New Drug Application (NDA) that preclude discussion of…